Merck plans to split human-health business into two divisions, WSJ says

Merck (MRK) is planning to split its human-health business into two divisions, one that will house its cancer drugs and the other will sell noncancer products, Peter Loftus of The Wall Street Journal reports. The moves are meant to prepare the company for a drop in Keytruda sales, since the immunotherapy accounts for nearly half of Merck’s sales, but is set to lose U.S. patent protection in 2028.